Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Rev Genomics Inc. has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners. All prosecution activity is concentrated within a distinct art unit. The company's current patent applications are being reviewed by multiple examiners despite being limited to a particular technical group.
DEQUANTARIUS JAVON SPEED is the busiest examiner, currently managing 1 pending action. This matches the workload of the other distinct examiners. The concentration of 3 pending actions within a distinct art unit suggests a specific technical focus despite the involvement of multiple examiners. Practitioners should note that while the pending office actions are in a single art unit, they are being reviewed by different individuals. This arrangement means that the matters are reviewed by different examiners. The pending office actions in the Biotechnology & Pharmaceuticals area are each assigned to a distinct examiner. This distribution ensures that each of the actions receives an independent evaluation within the 1 art unit.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPEED, DEQUANTARIUS JAVON | 1 | 70.0% | +69.2% |
| WILLIAMS, KEITH RICHARD | 1 | 44.4% | +0.0% |
| STOCKDALE, JESSICA NICOLE | 1 | 51.4% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18811676 | Self-Fertilization as Methods for Stabilizing Ploidy after Colchicine Treatment Model | WILLIAMS, KEITH RICHARD | 118d overdue |
| 17860013 | Submersion-Free Systems and Methods to Genetically Transform Cannabis Sativa | STOCKDALE, JESSICA NICOLE | 73d overdue |
| 19225975 | GIBBERELLIC ACID AND THE FORMATION OF MALE REPRODUCTIVE STRUCTURES ON FEMALE CANNABIS PLANTS | SPEED, DEQUANTARIUS JAVON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17860013 | Submersion-Free Systems and Methods to Genetically Transform Cannabis Sativa | STOCKDALE, JESSICA NICOLE | 73d overdue |
| 19225975 | GIBBERELLIC ACID AND THE FORMATION OF MALE REPRODUCTIVE STRUCTURES ON FEMALE CANNABIS PLANTS | SPEED, DEQUANTARIUS JAVON | — |
| Art Unit | Apps |
|---|---|
| 1663 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19225975 | GIBBERELLIC ACID AND THE FORMATION OF MALE REPRODUCTIVE STRUCTURES ON FEMALE CANNABIS PLANTS | SPEED, DEQUANTARIUS JAVON | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jun 02, 2025 |
| 18811676 | Self-Fertilization as Methods for Stabilizing Ploidy after Colchicine Treatment Model | WILLIAMS, KEITH RICHARD | 1663 | §102§103§112 | Non-Final OA | 118d overdue | Pending | Aug 21, 2024 |
| 17860013 | Submersion-Free Systems and Methods to Genetically Transform Cannabis Sativa | STOCKDALE, JESSICA NICOLE | 1663 | §103§112 | Final Rejection | 73d overdue | Pending | Jul 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRev Genomics Inc. has 3 pending office actions as of November 2026, spread across 1 art units and 3 examiners.
Dequantarius Javon Speed has the most, with 1 of Rev Genomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.